Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 25

November 17, 2022 00:39:44
Episode Cover

Episode 25: Jim Geraghty, Author and Biotech Industry Veteran

“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to...

Listen

Episode 14

November 10, 2021 00:46:16
Episode Cover

Episode 14: Bo Bigelow, Chairman at the Foundation for USP7-Related Diseases, and Trish Flanagan, President at the Yellow Brick Road Project

How will a rare disease diagnosis affect your family? Today's Few & Far Between episode features Bo Bigelow, Chairman at the Foundation for USP7-Related...

Listen

Episode 57

July 22, 2025 00:44:53
Episode Cover

Episode 57: Jim Brown, DVM, President and CEO of DURECT Corporation

Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host...

Listen